Literature DB >> 32672604

Estimating the Reliability of Glaucomatous Visual Field for the Accurate Assessment of Progression Using the Gaze-Tracking and Reliability Indices.

Ryo Asaoka1, Yuri Fujino2, Shuichiro Aoki2, Masato Matsuura2, Hiroshi Murata2.   

Abstract

PURPOSE: To investigate the usefulness of visual field (VF) reliability indices and gaze tracking (GT) for the accurate assessment of progression in glaucoma.
DESIGN: Institutional practice. PARTICIPANTS: Four hundred eighty-three eyes of 304 patients with open-angle glaucoma.
METHODS: In each eye, a series of 10 VFs were examined. Using the GT chart at the bottom of the VF printout (Humphrey Field Analyzer, Swedish interactive threshold algorithm standard), average tracking failure frequency (TFF), average blinking frequency (BF), and the total amount of eye movement per stimulus (MPS) were calculated. Mean total deviation (mTD) was calculated based on the 52 total deviation values in each 24-2 VF, and linear regression was applied to the series of mTD measurements over time. Progression was deemed to have occurred based on 2 separate definitions: (1) the mTD rate across all 10 VFs (VF1-10) was significant (P < 0.05) and less than 0 dB/year and (2) the mTD rate was less than -0.5 dB/year and significant at P < 0.05. The mTD rate also was calculated in shorter VF series (VF1-5-VF1-9). The area under the receiver operating characteristic curve (AUC) was calculated from the relationship between mTD rates of shorter VF series (n < 10) and the diagnosis of progression in all 10 VFs. This analysis was iterated after excluding eyes with increasingly strict cutoff values for the standard VF reliability indices (fixation loss [FL], false-positive [FP] rate, and false-negative [FN] rate) and the GT parameters (TFF, BF, and MPS). MAIN OUTCOME MEASURES: Area under the receiver operating characteristic curve values with different exclusion criteria for GT and standard reliability indices.
RESULTS: The AUC was largely unchanged according to stricter FL and FP criteria. The AUC increased with a more stringent FN criterion, but only when progression was described using the second definition (a rate of less than -0.5 dB/year). The AUC increased with stricter criteria for TFF, BF, and, to some extent, MPS.
CONCLUSIONS: Mean total deviation progression rates are more reliable when FN, TFF, BF, and MPS indices are stricter. Gaze-tracking results should be considered when assessing glaucomatous progression.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 32672604     DOI: 10.1016/j.ogla.2019.02.001

Source DB:  PubMed          Journal:  Ophthalmol Glaucoma        ISSN: 2589-4196


  5 in total

1.  Relationship between visual acuity and visual field and its reproducibility in patients with retinitis pigmentosa.

Authors:  Ryo Asaoka; Manabu Miyata; Akio Oishi; Yuri Fujino; Hiroshi Murata; Keiko Azuma; Ryo Obata; Tatsuya Inoue
Journal:  Eye (Lond)       Date:  2022-04-20       Impact factor: 3.775

2.  Association of Visual Field Pattern Reversal with Paracentral Visual Field Loss.

Authors:  Aimee C Chang; Andrew S Camp; Vincent M Patella; Robert N Weinreb
Journal:  Ophthalmol Glaucoma       Date:  2021-10-21

3.  Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.

Authors:  Jack Phu; Michael Kalloniatis
Journal:  Ophthalmic Physiol Opt       Date:  2022-05-22       Impact factor: 3.992

4.  Standard Reliability and Gaze Tracking Metrics in Glaucoma and Glaucoma Suspects.

Authors:  Andrew Steven Camp; Christopher P Long; Vincent Michael Patella; James A Proudfoot; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2021-07-17       Impact factor: 5.488

5.  The Human Touch: Using a Webcam to Autonomously Monitor Compliance During Visual Field Assessments.

Authors:  Pete R Jones; Giorgia Demaria; Iris Tigchelaar; Daniel S Asfaw; David F Edgar; Peter Campbell; Tamsin Callaghan; David P Crabb
Journal:  Transl Vis Sci Technol       Date:  2020-07-20       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.